Table 1.
Clinical demographics and results of exams in patients with TLE.
| No. | Age (range) | sex | onset age | Duration of TLE | Focus side | Seizure type | IED location | Anti-epileptic drugs | LT-VEEG | Hypometablic areas in FDG-PET |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 55–59 | F | 13 | 42 | L-TLE | FAS, FIAS | T3 | CBZ, TPM, PRM | Yes | LT, OL, IFG |
| 2 | 45–49 | M | 9 | 39 | L-TLE | FAS, FIAS | T3 | LEV, PRM, CBZ | No | MT, LT, OL |
| 3 | 45–49 | M | 29 | 19 | L-TLE | FIAS | T3 | CBZ, LTG | No | MT, LT |
| 4 | 40–44 | M | 9 | 31 | L-TLE | FIAS | T3 | CBZ, VPA, LCM, CZP | No | MT, LT |
| 5 | 40–44 | M | 20 | 23 | L-TLE | FIAS | T3 | CBZ, LEV | No | MT, LT |
| 6 | 25–29 | F | 19 | 8 | L-TLE | FIAS | T3 | CBZ, TPM | Yes | LT, OL, OFC |
| 7 | 70–74 | M | 65 | 7 | L-TLE | FAS, FIAS | T3 | CBZ | No | MT |
| 8 | 25–29 | M | 19 | 9 | L-TLE | FAS, FIAS | T3, T4 | CBZ, LEV, CLB | Yes | LT, MT |
| 9 | 30–34 | M | 24 | 8 | L-TLE | FIAS | T3 | CBZ, LTG, CZP | Yes | MT |
| 10 | 45–49 | F | 20 | 27 | L-TLE | FIAS | T3 | CBZ, CZP | Yes | MT |
| 11 | 40–44 | M | 32 | 9 | L-TLE | FIAS | F7 | LEV, CZP, ZNS, CLB | No | LT, MT, IFG |
| 12 | 15–19 | F | 14 | 3 | L-TLE | FIAS | T3 | CBZ, LEV | Yes | MT |
| 13 | 35–39 | M | 37 | 1 | L-TLE | FAS, FIAS | T3, T5 | LEV | No | MT |
| 14 | 25–29 | F | 25 | 2 | L-TLE | FIAS | T3 | CBZ | Yes | MT, LT |
| 15 | 40–44 | M | 11 | 30 | L-TLE | FAS, FIAS, FBTCS | F7 | PHT, CBZ | Yes | LT, MT, OL |
| 16 | 30–34 | F | 14 | 20 | L-TLE | FIAS, FBTCS | T3 | CBZ, ZNS | Yes | LT, OL |
| 17 | 20–24 | M | 24 | 0 | L-TLE | FIAS | T3 | LEV, VPA | No | LT, MT, OL |
| 18 | 65–69 | M | 37 | 30 | L-TLE | FIAS | T3 | VPA, CBZ | No | MT, LT |
| 19 | 40–44 | F | 38 | 2 | L-TLE | FIAS, FBTCS | T3, T4 | CBZ | Yes | MT, LT |
| 20 | 50–54 | M | 13 | 41 | L-TLE | FAS, FIAS | T3 | CBZ | No | MT, LT |
| 21 | 30–34 | F | 30 | 2 | L-TLE | FAS, FIAS | T3 | LEV | Yes | LT |
| 22 | 20–24 | M | 20 | 4 | L-TLE | FIAS, FBTCS | F7, T3 | VPZ, CBZ | Yes | LT, MT, OFC, OL |
| 23 | 15–19 | M | 14 | 3 | L-TLE | FAS, FIAS | T1 | ZNS, LEV | Yes | MT, LT |
| 24 | 45–49 | M | 26 | 21 | R-TLE | FIAS | T4 | CBZ, VPA | No | MT, LT |
| 25 | 50–54 | F | 22 | 29 | R-TLE | FIAS | T4, T3 | CBZ | Yes | LT |
| 26 | 30–34 | M | 15 | 16 | R-TLE | FAS, FIAS | T4 | LEV, CBZ, PHT | No | MT |
| 27 | 45–49 | F | 7 | 42 | R-TLE | FIAS | T4 | CBZ, VPA, CLB | No | LT, IFG, operculum |
| 28 | 25–29 | M | 6 | 22 | R-TLE | FAS, FIAS | T4 | CBZ, LTG, CZP | Yes | MT, LT, IFG, operculum |
| 29 | 30–34 | F | 6 | 25 | R-TLE | FAS, FIAS | F8 | CBZ | Yes | LT |
| 30 | 55–59 | M | 54 | 5 | R-TLE | FIAS | F8 | ZNS, LEV | No | MT |
| 31 | 15–19 | M | 11 | 6 | R-TLE | FAS, FIAS | T4, T6 | PHT, LEV, CBZ | Yes | MT, LT, OL |
| 32 | 25–29 | M | 9 | 19 | R-TLE | FAS, FIAS | T3, T4 | PHT, LEV, TPM | Yes | MT, LT |
| 33 | 40–44 | F | 20 | 23 | R-TLE | FAS, FIAS | T4 | CBZ | No | LT, MT, OL |
| 34 | 25–29 | F | 20 | 8 | R-TLE | FAS, FIAS, FBTCS | F8, T4 | VPA, CBZ | Yes | MT, LT |
| 35 | 35–39 | M | 10 | 27 | R-TLE | FAS, FIAS | F8, F7 | CBZ, LEV | Yes | LT, OL |
| 36 | 30–34 | M | 32 | 2 | R-TLE | FIAS, FBTCS | F8 | CBZ, LEV | No | LT |
| 37 | 35–39 | F | 28 | 7 | R-TLE | FAS, FIAS, FBTCS | T4 | CBZ | No | LT |
| 38 | 35–39 | F | 3 | 34 | R-TLE | FAS, FIAS | T4 | CBZ, VPA | Yes | LT |
| 39 | 40–44 | F | 20 | 23 | R-TLE | FIAS | T4 | CBZ, VPA, CLB | Yes | MT, LT, OFC |
| 40 | 40–44 | F | 17 | 25 | R-TLE | FIAS | T4 | PHT, LTG | No | LT, MT, OL, operculum |
| 41 | 55–59 | F | 56 | 2 | R-TLE | FIAS | T3 | VPA | No | MT, LT |
| 42 | 20–24 | F | 3 | 20 | R-TLE | FAS, FIAS | T4 | LEV, CBZ, PHT | Yes | MT, LT |
CBZ, carbamazepine; CLB, clobazam; CZP, clonazepam; EEG, Electroencephalography; FAS, focal aware seizures; FBTCS, focal to bilateral tonic-clonic seizures; FIAS, focal impaired awareness seizures; IED, interictal epileptiform discharge; IFG, inferior frontal gyrus; LCM, lacosamide; LEV, levetiracetam; LT, lateral temporal lobe; LT-VEEG, long-term video-EEG monitoring; LTG, lamotrigine; PHT, phenytoin; PRM, primidone; MT, mesial temporal lobe; NZP, nitrazepam; OFC, orbitofrontal cortex; OL, occipital lobe; TPM, topiramate; VPA, valproate; ZNS, zonisamide.